In Vitro Activity of API-1252, a Novel FabI Inhibitor, against Clinical Isolates of Staphylococcus aureus and Staphylococcus epidermidis
- 1 April 2007
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (4), 1580-1581
- https://doi.org/10.1128/aac.01254-06
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Community-associated Methicillin-resistantStaphylococcus aureus, CanadaEmerging Infectious Diseases, 2005
- Discovery of a Novel and Potent Class of FabI-Directed Antibacterial AgentsAntimicrobial Agents and Chemotherapy, 2002
- Multiplex PCR Strategy for Rapid Identification of Structural Types and Variants of the mec Element in Methicillin-Resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2002
- Inhibitors of fatty acid synthesis as antimicrobial chemotherapeuticsApplied Microbiology and Biotechnology, 2002
- Bacterial Fatty Acid Biosynthesis: Targets for Antibacterial Drug DiscoveryAnnual Review of Microbiology, 2001
- Development of a Canadian Standardized Protocol for Subtyping Methicillin-Resistant Staphylococcus aureus Using Pulsed-Field Gel ElectrophoresisJournal of Clinical Microbiology, 2001
- Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typingJournal of Clinical Microbiology, 1995